Clinical trials: Thoracic Neoplasms
Lung Cancer
Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective in treating non-small cell lung cancer.
- Trial name
- NCT00022022
- Testing
- docetaxel, quality-of-life assessment
- Where
- 16 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Nazionale per lo Studio e la Cura dei Tumori
NSCLC Stage IV, NSCLC, Stage III
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC
Primary Objectives: To evaluate the Quality of Life (QoL) score of adding oral Oligo Fucoidan to platinum-based chemotherapy in comparison with placebo in subjects with Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT03130829
- Testing
- Oligo Fucoidan
- Where
- 3 sites in Taiwan
- Sponsor
- Hi-Q Marine Biotech International, Ltd.
Stage III Non-small Cell Lung Cancer
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and…
- Trial name
- NCT01102231
- Testing
- Chemotherapy, ERBITUX, Radiotherapy
- Where
- 38 sites in France
- Volunteers
- 106 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Neoplasm
Single-port, Two-port Versus Three-port VATS on Non-small Cell Lung Cancer
In china, the incidence and death rate of lung cancer is 48.32 per 100 000 person-years and 39.27 per 100 000 person-years, respectively, the highest in malignant tumor.
- Trial name
- NCT02992353
- Testing
- Three-port pulmonary resection surgery, Single-port or two-port surgery
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer
Radiomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
The purpose of this study is to evaluate relationships between multiparametric imaging biomarkers and genetic analysis in NSCLC patients.
- Trial name
- NCT01585545
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Samsung Medical Center
Mediastinal Lymphadenopathy, Hilar Lymphadenopathy
Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies
The main purpose of the present study is to assess whether the sensitivity of Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) is superior to that of conventional TBNA in the diagnosis of hilar/mediastinal…
- Conditions
- Mediastinal Lymphadenopathy, Hilar Lymphadenopathy, Lymphoma, Lung Neoplasms
- Trial name
- NCT01658280
- Testing
- EBUS-TBNA
- Where
- Italy
- Volunteers
- 253 people
- Sponsor
- Azienda Ospedaliero, Universitaria Ospedali Riuniti
Psychosocial
Effects of Cancer Symptoms on Caregivers
The primary objectives are to: 1.1 identify and compare the experiences of minority and nonminority caregivers, including the prevalence and severity of physical (fatigue, sleep disturbance) and psychologic (depression, anxiety…
- Trial name
- NCT00351988
- Testing
- Phenomenological Interviews, Quantitative Interviews
- Where
- 4 sites in United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer Stage III
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
This is a phase II, single-arm, open-label study to evaluate the efficacy and safety of the third generation tyrosine kinase inhibitors (TKIs) Almonertinib (HS-10296) as neoadjuvant and adjuvant therapy for potential resectable…
- Trial name
- NCT04685070
- Testing
- HS-10296 (Almonertinib)
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer Stage IV
Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer
Patients with metastatic non-small cell lung cancer (NSCLC) who after an initial response to immunotherapy of chemo-immunotherapy show diffuse disease progression are treated with chemotherapy, with a median PFS of about 3 months…
- Trial name
- Re-Induce 2 (NCT06024941)
- Testing
- Radiation
- Where
- Netherlands
- Sponsor
- Maastricht Radiation Oncology
Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects and best dose of veliparib when given together with or without cisplatin and etoposide and to see how well they work in treating patients with extensive stage small cell…
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma, Neuroendocrine Carcinoma, Small Cell Carcinoma
- Trial name
- NCT01642251
- Testing
- Cisplatin, Etoposide, Veliparib
- Where
- 428 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer (NSCLC)
Digital Lifestyle Intervention for Lung Cancer Survivors
The aim of this study is to assess the efficacy of a digital lifestyle intervention in non-small cell lung cancer (NSCLC) survivors on health-related quality of life (HRQoL) over three months.
- Trial name
- QUALUCA (NCT05819346)
- Testing
- Lifestyle
- Where
- 4 sites in Switzerland
- Volunteers
- 21 people
- Sponsor
- Kai-Uwe Schmitt, PhD, MEng, ICID
Lung Cancer
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00062322
- Testing
- cisplatin, irinotecan hydrochloride, conventional surgery
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Lung Cancer, Nonsmall Cell
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
Patient selection: a) Pathological confirmation of non-small cell lung cancer without activating EGFR mutations; b) Advanced stage disease (IV or IIIB with malignant effusion) with at least two prior chemotherapy regimens; c) No…
- Trial name
- NCT02991651
- Testing
- IRX4204, erlotinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Io Therapeutics
Lung Cancer, Malnutrition
Assessment of Relationship Between Preoperative Nutritional Status and Perioperative/Postoperative Conditions in Patients With Lung Cancer Scheduled for Lobectomy
Malnutrition is common in patients with lung cancer. In patients with malnutrition risk, the risk of complications is high both in the perioperative, early and late postoperative periods.
- Conditions
- Lung Cancer, Malnutrition, Nutritional Deficiency
- Trial name
- NCT05417672
- Testing
- Nutritional Risk Screening-2002, Nutritional Risk Index, Mini Nutritional Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 63 people
- Sponsor
- Turkish Society of Anesthesiology and Reanimation
Non-Small Cell Lung Cancer
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
This is a single arm study, conducted at two centers, of neoadjuvant sotorasib in treatment naïve patients with stage Ib-IIIa NSCLC. The study will accrue 25 patients in all.
- Trial name
- NCT05400577
- Testing
- Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Lung Cancer, Non-small Cell
Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)
For unresectable locally advanced non-small cell lung cancer (LA-NSCLC), the standard treatment at present is concurrent chemoradiation therapy (CCRT) followed by durvalumab consolidation therapy.
- Trial name
- CHIC (NCT05784142)
- Testing
- hypofractionated radiation therapy
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma
- Trial name
- NCT07405086
- Testing
- Biospecimen Collection, Immune Checkpoint Inhibitor
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- OHSU Knight Cancer Institute
Lung Cancer
Study of Tissue Samples From Patients With Stage I Non-Small Cell Lung Cancer Enrolled on Research Study CALGB-140202
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
- Trial name
- NCT00990873
- Testing
- gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small Cell Lung Cancer
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2)…
- Trial name
- NCT04297605
- Testing
- Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Rochester
Lung Cancer
Characteristics of Mediastinal Lymph Node With False Positive FDG PET/CT Results in Lung Cancer Staging : Relation With TB and Latent TB Infection
The purpose of this study is to analyze pathologic and radiologic characteristics of mediastinal lymph nodes with false positive FDG PET/CT results in lung cancer staging and assess relationship between false positive mediastinal…
- Trial name
- NCT01376856
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Yonsei University